Eli Lilly CEO Ricks on Sales Forecast, Alzheimer's Drug

The transcript discusses Eli Lilly's response to the COVID-19 pandemic, highlighting their development of neutralizing antibodies and anti-inflammatory medications. It also covers their Alzheimer's research, focusing on the FDA's policy shift and the company's leading product, Dona map. The discussion includes the controversy surrounding Alzheimer's drug pricing and the company's competitive strategies. Additionally, Eli Lilly's vaccination policy and concerns about the Delta variant's transmissibility are addressed.

How does Eli Lilly plan to address the controversy surrounding the pricing of their Alzheimer's drug?

What differentiates Eli Lilly's Alzheimer's drug from others currently being studied?

What is Eli Lilly's current stance on requiring vaccinations for their employees?